OET Published in MediaPlanet’s Value of Vaccines Campaign Magazine
We’re proud to have been involved in Media Planet’s Value of Vaccines campaign and contributing to an outstanding edition of their magazine. We talk more about our current research & development project, working on making a vaccine for the Crimean Congo Haemorrhagic Fever (CCHF). Read our article here or browse the full edition below! #ValueofVaccines
OET awarded a share of £10m for vaccine research to combat epidemics in developing countries
Oxford Expression Technologies Ltd (OET) is pleased to announce that it has been awarded £377K, one of 22 successful awards, as part of the ‘SBRI – Vaccines for epidemic diseases: Readiness for clinical development and regulatory submission’ programme. This research is funded by the Department of Health and Social Care as part of the UK […]
Latest Academic Paper from OET
Optimizing Recombinant Baculovirus Vector Design for Protein Production in Insect Cells
John Harris joins OET as Chair of the Board of Directors
Oxford Expression Technologies is delighted to welcome John Harris as Chair of the Board of Directors. John brings to OET extensive leadership, Board, and managerial competence developed within well respected Blue-Chip, Governmental and SME organisations specialised in the Life Sciences Sectors. Over his 37 years working in this space (including 23 years at CEO level), […]
OET in Top 5 Virology Solution Providers 2021
OET is delighted to be featured as one of the top 5 virology solution providers for 2021 in the annual Pharmatech Outlook Awards. The full listing can be found here An interview with Prof Linda King, founder and CEO of Oxford Expression Technologies can be found here.
flashBAC chosen to produce proteins for Dengue and Zika antibody tests
Oxford Expression Technologies is delighted that their flashBAC TM expression system was chosen as the tool to produce the glycoproteins for the development of a novel antigen lateral flow antibody test for dengue and Zika. Details of the project are described in this press release from Excivion Ltd.